Garvinci Company

Garvinci is a privately-held Canadian company focused on arthritis and women's health. The Company was founded in 2001 by Jean-Francois Gareau, a Montreal entrepreneur. Garvinci's principal assets are the Canadian distribution rights to a line of ostearthritis products and the Canadian distribution rights to the morning after pill NorLevoВ® from the French company, Laboratoire HRA Pharma S.A. The osteoarthritis products include a visco-supplement product to relieve the symptomatic pain associated with osteoarthritis of the hip, shoulder and knee. Garvinci is also in discussions concerning Canadian rights to additional products such as a visco-supplement for smaller joint and a synovial fluid replacement product for relief of pain following arthroscopy. Garvinci has received Notice of Compliance and a DIN number from Health Canada for the HRA Pharma product NorLevoВ®, a morning-after emergency contraceptive pill, and is currently in discussions with a senior pharmaceutical company to supplement Garvinci's marketing capabilities.

Founded Date: 01.01.2001
Last Funding Type: N/A
Headquarters: Montreal, Canada
Technology: Specific disorder-related
Employee Number: N/A
Industry: Treatment range
Estimated Revenue: $0
Last Funding Date: N/A
Funding Status: N/A
Investor Type: For Profit
Total Funding: $0
N/A
Register and Claim Ownership